Manuel Quaresma
Ingelheim Am Rhein, RP, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study.
Journal: Experimental dermatology
Published: January 31, 2023
Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study.
Journal: Journal of the American Academy of Dermatology
Published: August 16, 2022
Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares.
Journal: Dermatology (Basel, Switzerland)
Published: July 09, 2022
Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double-blind, placebo-controlled Effisayil™ 1 study.
Journal: The Journal of dermatology
Published: June 27, 2022
Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: March 11, 2021
Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: July 13, 2020
Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial.
Journal: The European respiratory journal
Published: May 01, 2020
Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis.
Journal: Respiratory research
Published: April 06, 2020
Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
Journal: Advances in therapy
Published: December 23, 2019
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Journal: The Lancet. Respiratory medicine
Published: November 18, 2019
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Journal: The New England journal of medicine
Published: October 01, 2019
Last Updated: 09/26/2026